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Graves’ disease after the initiation of highly active antiretroviral therapy (HAART) in certain HIV-1-infected individuals has been
describedasanimmunereconstitutioninﬂammatorysyndrome(IRIS).Thisphenomenonshouldbesuspectedinindividualswho
present with clinical deterioration and a presentation suggestive of hyperthyroidism despite good virological and immunological
response to HAART. Signs and symptoms of hyperthyroidism may be discrete or overt and typically develop 8–33 months after
initiating therapy. One to two percent of HIV-infected patients can present with overt thyroid disease. Relatively few cases of
Graves’ IRIS have been reported in the literature to date. We describe four cases of Graves’ IRIS in HIV-infected patients who were
started on HAART therapy.
1.Introduction
The beginning of the highly active antiretroviral therapy
(HAART) era around 1995 signaled a paradigm shift in the
clinical outcome of patients infected with HIV as reﬂected
by a signiﬁcant improvement in overall survival [1]. Patients
with HIV infection, who are on HAART, achieve restoration
of previously compromised immune function, resulting in
decreasedmortalityandmorbidityfromopportunisticinfec-
tions [2]. However, a minority of patients might experience a
paradoxical clinical decline as a result of immune restitution
[2]. This phenomenon occurs by virtue of restoration of the
capacity to mount an inﬂammatory response against both
infectious and noninfectious antigens [3], hence the term
immune reconstitution inﬂammatory syndrome (IRIS).IRIS
occurs most commonly as a result of reactivation of infec-
tions such as Mycobacterium avium complex, Mycobacterium
tuberculosis, Cryptococcus neoformans, or cytomegalovirus
and tends to occur between a few weeks and several months
after initiating HAART, corresponding with CD4 positive
memory cell repopulation [4].
Thedevelopmentofavarietyofautoimmunediseaseshas
been reported in patients infected with HIV. Autoimmunity
may occur due to the loss of immune competence but may
also appear after commencement of HAART [5]. Indeed,
autoimmunity as a consequence of immune reconstitution
has been recognized as an unfavorable event in HIV-1-
positive individuals. Graves’ disease resulting from immune
restoration has had relatively recent recognition and might
be viewed as a consequence of organ-speciﬁc autoimmunity
during the late period of T-cell repopulation, speciﬁcally of
CD4 positive na¨ ıve cells [6]. We report four cases of Grave’s
IRIS in our practice. The detailed demographics and HIV-
related history is summarized in Table 1 and thyroid-related
workup and management in Table 2.
Case 1. A 34-year-old African American male with a
CD4 T-cell count of 59cells/μL and HIV RNA level
>750,000copies/mL was started on stavudine, abacavir,
lamivudine and efavirenz. Forty-four months later, he
presented with weight loss, alopecia, diarrhea, palpitations,
lid lag, and thyromegaly. Thyroid function tests revealed
elevated free T4 and thyroid peroxidase antibody (TPO-
Ab) levels, with undetectable thyroid stimulating hormone
(TSH) levels. A thyroid ultrasound revealed multinodular
c h a n g e sw i t hd i ﬀuse enlargement of the gland. He was2 AIDS Research and Treatment
Table 1: Demographic, immunological and virological data for the cases described.
No. Year Age Sex Race HIV diagnosis HAART start Baseline CD4
count (cells/μL)
CD4count
at symptoms
(cells/μL)
HIV RNA
change
(copies/mL)
HAART
regimen
(1) 2003 34 M African
American March 1993 June 1999 59 341 >750,000 to 775
Stavudine
Abacavir
Lamivudine
Efavirenz
(2) 2007 42 M African
American December 2002 December 2002 89 537 205 to <50
Lamivudine
Zidovudine
Efavirenz
(3) 2007 39 M African April 2005 April 2005 59 250 <50 to <50
Tenofovir
Emtricitabine
Efavirenz
Tenofovir
(4) 2008 43 F African
American March 2006 October 2006 29 462 252,984 to <50 Emtricitabine
Efavirenz
Table 2: Thyroid workup and management (FT4: free T4, TSH: thyroid stimulating hormone, TPO-Ab: thyroid peroxidase antibody, TBG-
Ab: thyroglobulin antibody, PTU: propylthiouracil).
No. Thyroid Work Up Time till
symptoms Symptoms
Previous
thyroid
condition
HCV
coinfection Treatment
History of
autoimmune
disease
(1)
FT4: 7.43ng/dL
TSH < 0.01MIU/mL
TPO-Ab: 46.7IU/mL
TBG-Ab < 1IU/mL
44 months
Thyromegaly, lid lag,
weight loss, alopecia,
diarrhea, and
tachycardia
No No
Methimazole
I-131
radioablation
No
(2)
TSH < 0.01MIU/mL
FT4: 3.3ng/dL
Diﬀu s eu p t a k eo n
thyroid scan
53 months
Tremor, weight loss,
exophthalmos, and
thyromegaly
No No Methimazole
atenolol No
(3)
TSH < 0.004MIU/mL
T4: 12.2ng/dL
TBG-Ab: 40IU/mL
31 months
Weight loss, tremor,
exophthalmos, lid lag,
and fatigue
No No PTU metoprolol No
(4) Not available 19 months
Tremors, weight loss,
loss of appetite,
thyromegaly, and
exophthalmos
No No methimazole
metoprolol No
treated with methimazole and ultimately I-131 radioablation
with complete resolution of symptoms.
Case 2. A 42-year-old African American male with a nadir
CD4 T-cell count of 89cells/μL and HIV RNA level of
205copies/mL initiated a regimen of lamivudine, zidovu-
dine, and efavirenz with good response. Fifty-three months
later, he presented with weight loss, tremor, exophthalmos,
and an enlarged thyroid gland. Thyroid function tests were
consistent with hyperthyroidism with an enlarged thyroid
glandonultrasound.Thyroidscintigraphydemonstratedthe
elevated uptake of I-123. He was managed successfully with
methimazole and atenolol.
Case 3. A 39-year-old African male presented with a CD4
T-cell count of 59cells/μL and an undetectable HIV RNA
level. He was treated with tenofovir/emtricitabine/efavirenz.
Within thirty-one months, he presented with palpitations,
tremors, fatigue, and weight loss. The thyroid gland was
enlarged. Thyroid function tests revealed an undetectable
TSH with high free T4 and antithyroglobulin antibodies.
Graves’ disease was managed with metoprolol and propylth-
iouracil with complete clinical response.
Case4. A43-year-oldAfricanAmericanfemalehadaninitial
CD4 T-cell count of 29cells/μL and HIV RNA level of 252,
984copies/mL. She began tenofovir/emtricitabine/efavirenz
and tolerated HAART well. Nineteen months later, she
experienced tremor, weight loss, and diarrhea with reduced
appetite. Her thyroid gland was enlarged and pulsatile, and
she had exophthalmos with a lid lag. Her condition was
managed with methimazole and metoprolol.AIDS Research and Treatment 3
2. Discussion
Autoimmunity has been described in untreated HIV
infection; however, apart from immune thrombocytope-
nia, reports of organ-speciﬁc autoimmunity are few [2].
Rheumatoid factor, ANA, and antiphospholipid antibodies
may be found in HIV-infected individuals without clinical
correlation [7]. Graves’ disease has in recent times been
describedintheliteratureasadocumentedIRISamongHIV-
infectedpatients.Graves’sdiseaseusuallyoccursafterarisein
the CD4 T-cell count; however, its unique nature is typiﬁed
by its late presentation, usually 8–33 months after starting
HAART [4, 8, 9].
Graves’ IRIS was initially described by Gilquin et al. in
1998 when they described 3 cases [10]. Brieﬂy following this,
Jubault et al. studied these cases in detail in conjunction
with 2 other cases [7]. Since the initial description, the
number of cases reported has been low. Crum et al. provided
a comprehensive review of 28 cases known at the time of
description [11]. In our patients, the median duration of
diagnosis of Graves’ IRIS after the initiation of antiretroviral
therapy was 37.5 months (range 19–53 months) compared
to a range of 14–22 months described in initial reports
[2, 7]. Our patients were predominantly black males (75%)
in comparison with previously available data where 19/28
(67.8%) were predominantly black females [8, 10].
The median CD4 T-cell nadir in our patients was
59cells/μL (range 29–89cells/μL), and the median rise in
CD4 T-cell count until the time of developing symptoms
was 357.5cells/μL (range 191–448cells/μL). All patients had
drastically reduced or undetectable viral loads at the time of
diagnosis of Graves’ IRIS. Like all other cases described in
the literature, none of our cases had a pre-existing thyroid
condition. In addition, there was no documented history
of other autoimmune diseases. None of our patients was
coinfected with hepatitis C or ever treated with interferon.
We,therefore,inferredthattheclinicalpictureofourpatients
was consistent with Graves’ IRIS.
Reconstitution Graves’ disease has been described to
occur in 3 clinically distinct settings [8]. Bone marrow
transplantation from a donor who has Graves’ disease may
cause this disease to surface in the recipient. Alemtuzumab
treatment for multiple sclerosis may also generate the
development of Graves’ disease in up to a third of patients.
Finally, reconstitution Graves’ disease may follow HAART
in HIV-1 infected individuals. Chaotic immunoregulation
due to graft-versus-host disease might play a pathogenic
role in bone marrow transplant recipients, whereas na¨ ıve
CD4 T-cell expansion has been hypothesized as the major
causative mechanism in the Alemtuzumab and HAART-
induced reconstitution Graves’ disease [8].
In the ﬁrst 2-3 months following HAART, HIV replica-
tion is suppressed, and the release of memory T cells from
inﬂamed lymphoid tissues leads to a rapid increase in the
previously low CD4 T-cell numbers [4, 8]. After this period,
naive CD4 T-cell numbers slowly improve as a result of
repopulation and new thymic production. Graves’ disease
may also be associated with Interferon Alpha (IFNα) used
to treat hepatitis C and Interleukin 2 (IL-2) therapy in
the setting of HIV [3, 9]. Earlier studies found that TPO
antibodies and TSH receptor antibodies appeared after CD4
T cells had dramatically increased on HAART, whereas they
were repeatedly absent prior to HAART [7]. The occurrence
of Graves’ disease in some reports was closely associated with
the rise of TSH receptor antibodies [6, 7].
Disordersofthyroidfunctionarecomparativelycommon
in the HIV population. Among individuals infected with
HIV, 1%-2% might experience clinically apparent thyroid
disease, and 35% may have subtle defects in thyroid function
test ﬁndings [12]. In addition to Graves’ disease, numerous
other thyroid disorders have been noted in HIV includ-
ing overt hypothyroidism, subclinical hypothyroidism, sick
euthyroid syndrome, and thyroiditis caused by opportunistic
infections or inﬁltrative processes [8, 12]. It is largely
unknown why only certain individuals develop Graves’
diseaseaspartofanimmunereconstitutionprocessalthough
various polymorphisms in diﬀerent cytokine and MHC
genes have been identiﬁed or hypothesized in diﬀerent
studies [6–9].
Whereas the pathogenic role of speciﬁc HAART agents
has not yet been validated, there has been speculation about
this possibility over the years. Most studies, however, argue
that Graves’ IRIS is more of a consequence of immune
reconstitution rather than a matter of how such reconstitu-
tion is achieved. Recently, a large single center cohort study
described thyroid disorders in HIV patients over a course
of 11 years [13]. In this cohort involving 2437 individuals,
the clinical prevalence of hyperthyroidism was 1.01%, and
that of hypothyroidism was 1.2%. Hypothyroidism was
most commonly associated with a protease inhibitor-based
regimen and hyperthyroidism with non-nucleoside reverse
transcriptase inhibitors, particularly efavirenz [13]. All the
four patients we have described were also on a regimen con-
taining efavirenz. Although this might reﬂect the frequent
use of efavirenz in initial HAART regimen, a direct role of
thisagentinthepathogenesisofautoimmunethyroiddisease
in HIV-infected individuals can be speculated.
3. Conclusion
Graves’ IRIS should be suspected if an HIV-infected indi-
vidual presents with weight loss or other signs of hyper-
thyroidism despite adequate and sustained immunological
and virological control. In HIV patients, measurement of
TSH level is appropriate for those with signs or symptoms
suggestive of thyroid dysfunction. There may be a need
to evaluate the role of speciﬁc antiretroviral agents in
the pathogenesis of Graves’ IRIS. Longitudinal studies are
required to further elucidate the eﬀect of HAART in general
on thyroid antibodies and to possibly delineate clinical risk
factors or predictors for developing Graves’ IRIS.
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